COMP <GO>
TNGX vs ABCL // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Tango Therapeutics Inc. (NASDAQ) VS. AbCellera Biologics Inc. (NASDAQ) • 15-METRIC TALLY: TNGX 3
— ABCL 4
■ METRIC PARITY
LAST: $21.76 (-4.22%) • MKT CAP: $3.83B
options-implied-move
—
LAST: $11.12 (-9.37%) • MKT CAP: $3.97B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNGX VS. ABCL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TNGX | ABCL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.90% | -20.50% | -8.40 | ABCL | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.68% | -4.11% | +0.43 | TNGX | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 48.30% | 160.60% | -112.30 | ABCL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 6.60 | +19.40 | TNGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | TNGX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.9 | 49.0 | -2.10 | ABCL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.83B | $3.97B | -$143.5M | ABCL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TNGX REV | ABCL REV | TNGX GROSS % | ABCL GROSS % | TNGX FCF | ABCL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $62.4M | $75.1M | — | — | -$139.9M | -$174.1M |
| FY 2024 | $42.1M | $28.8M | — | — | -$132.3M | -$187.0M |
| FY 2023 | $36.5M | $38.0M | — | — | -$119.6M | -$43.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNGX // BETA 0.87
ABCL // BETA —